Dudediligence.

Ernexa Therapeutics Inc

ERNANASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$487,000Sep ’24$1,000Dec ’24
Net income, by quarter
−$26.6MSep ’24−$5.8MDec ’24−$8.2MMar ’25−$3.1MJun ’25−$1.2MSep ’25−$1.5MDec ’25−$5.5MMar ’26−$4.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on file$0.00$68,000$582,000none on file
Gross profitnone on file$0.00−$168,000$486,000none on file
Operating income−$113.7M−$33.2M−$21.1M−$15.7M−$9.3M
Net income−$122.5M−$24.6M−$21.7M−$44.5M−$14.1M
Operating cash flow−$23.5M−$21.0M−$20.4M−$15.8M−$7.0M
Free cash flow−$23.6M−$21.3M−$20.4M−$16.2M−$7.1M
Cash$17.0M$15.5M$11.7M$1.7M$1.9M
Shares outstanding2.6M5.1M5.4M3.4M7.9M